Skip to main
CDMO
CDMO logo

Avid Bioservices (CDMO) Stock Forecast & Price Target

Avid Bioservices (CDMO) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Avid Bioservices Inc. demonstrates strong growth potential due to ongoing capacity expansions that are expected to more than double its revenue-generating capabilities within the next three years. The company's existing facilities offer significant opportunities for expansion, which is anticipated to generate high incremental margins, supporting a projected double-digit revenue compound annual growth rate (CAGR) and meaningful EBITDA margin expansion. Additionally, improvements in bookings momentum contribute positively to the overall demand outlook, further solidifying Avid's revenue guidance for fiscal year 2025 and enhancing visibility into its longer-term growth prospects.

Bears say

Avid Bioservices is facing several fundamental challenges that contribute to a negative outlook on its stock. The company's recent revenue miss, coupled with higher-than-expected selling, general, and administrative expenses resulting in a shortfall in EBITDA, indicates a trend of operational difficulties, particularly in the contract development and manufacturing organization (CDMO) segment. Additionally, external factors such as potential customer insourcing, a pullback in biotech funding, and intense competition raise concerns about revenue stability and growth, threatening the company's long-term profitability.

Avid Bioservices (CDMO) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Avid Bioservices and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Avid Bioservices (CDMO) Forecast

Analysts have given Avid Bioservices (CDMO) a Buy based on their latest research and market trends.

According to 7 analysts, Avid Bioservices (CDMO) has a Buy consensus rating as of Jul 28, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Avid Bioservices (CDMO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.